

02 Mar 2023 | Interviews

# Cardio Conversations: Abbott's Electrophysiology CMO Christopher Piorkowski On Cardiac Mapping, PFA, VT And More

by

In this episode of *Medtech Insight's* new podcast series focused on cardiovascular technology, editor Reed Miller talked to Christopher Piorkowski, Abbott's chief medical officer for electrophysiology.

After a two-decade career as a electrophysiologist specializing in complex cardiac arrhythmias, Christopher Piorkowski left his job as the head of the department of electrophysiology at the University of Dresden to join [Abbott](#) in 2020.

As the chief medical officer of Abbott's electrophysiology business, Piorkowski has "an opportunity [to] build future medical technology [and] help many patients – not only the one on the table," he told *Medtech Insight*. "So far the experience has been outstanding."

According to [Meddevicetracker](#), Abbott has the second largest share of the cardiac ablation device market behind [Johnson & Johnson/Biosense Webster](#), but ahead of [Medtronic](#) and [Boston Scientific](#).

Abbott is depending on the EnSite X arrhythmia mapping system to maintain its position in this increasingly competitive market. "We are building the most accurate, most user-friendly and most flexible tracking technology in the field of electrophysiology." (Also see "[Abbott Launches Next-Generation Of EnSite Cardiac Mapping System](#)" - Medtech Insight, 5 Nov, 2020.)

The company is also continuing to push innovation in cardiac ablation technology, including pulsed field ablation (PFA), but all of those advanced tools will be designed around EnSite, he said. (Also see "[News We're Watching – LivaNova And Medtronic Recalls; Approvals For Abbott And Guardant; Pediatric Device Grants](#)" - Medtech Insight, 3 Feb, 2023.)

"The EnSite X system is really the foundation of our future," he said

Medtech Insight editor Reed Miller recently interviewed Piorkowski to learn more about the company's technological and market strategy, his priorities in the company, and more.

*Use the player below to hear the whole interview.*

[Click here to explore this interactive content online](#) ✎

*For more information on some of the newest electrophysiology advancements discussed in this interview, check out these articles from Medtech Insight.*

[Abbott Announces EU And US Approvals On Cardiac Ablation Catheters](#)

[US FDA Approves Abbott's Sensor-Enabled TactiCath AF Catheter](#)

[Abbott Launches Next-Generation Of EnSite Cardiac Mapping System](#)

[Cardio Conversations: Steven Mickelsen Discusses PFA, Electrophysiology And What It Takes To Be A Physician Inventor](#)

[JPM 2023: Boston Scientific Sees Transformational Potential In PFA, BD Sticks To '2025' Investment Strategy](#)

[Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story \(Part II\)](#)

[Starts & Stops: Abbott Launches LESS-VT Trial Of FlexAbility Catheter](#)

## Further Listening

Our other podcasts are available on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.